华夏时报（www.chinatimes.net.cn）记者 郭怡琳 于娜 北京报道 近日，"伽玛刀之王"西安大医集团股份有限公司（下称：大医集团）再次递表港交所，拟通过第18A章登陆港股 市场。 值得注意的是，距离大医集团上次冲击IPO已经过去4年。早在2021年6月，大医集团曾递表上交所科创板，却在 半年后主动申请撤回上市申请。对比前后两份招股书，此次大医集团的联席保荐人为中信建投国际、浦银国际、 民银资本，而2021年的保荐人仅海通证券。 对此，大医集团解释称，其曾与海通证券订立辅导协议并在上交所递交上市申请，但是由于A股整体审批程序及 当时不利市况令上市时间表不明朗，于2021年底主动撤回A股上市申请，并决定寻求在港交所上市。 招股书显示，大医集团专注于肿瘤诊疗与放疗产品，主营业务是创新放疗设备的研发、生产、销售、服务。虽然 在所有中国伽玛放射外科医疗设备企业中，大医集团以75.8%的市场份额排名第一。但在中国放射治疗医疗设备 市场上所占份额并不高，2024年的市场份额仅4.7%。在有商业化产品的前提下亏损逐年扩大，2018—2020年归母 净利润分别亏损约4380万元、840万元、1770万元；202 ...

Company Overview - Tandem Diabetes Care, Inc. (TNDM) has seen its shares increase by approximately 6.5% over the past month, outperforming the S&P 500 [1] - The most recent earnings report is crucial for understanding the key drivers affecting the stock [1] Earnings Estimates - Estimates for Tandem Diabetes Care have trended downward over the past month, with the consensus estimate shifting by -19.45% [2] - The stock currently holds a Zacks Rank of 3 (Hold), indicating expectations for an in-line return in the coming months [4] VGM Scores - Tandem Diabetes Care has an average Growth Score of C, a Momentum Score of F, and a Value Score of C, placing it in the middle 20% for the value investment strategy [3] - The overall aggregate VGM Score for the stock is D, which is significant for investors not focused on a single strategy [3] Industry Performance - Tandem Diabetes Care is part of the Zacks Medical - Instruments industry, where another player, Intuitive Surgical, Inc. (ISRG), has gained 7.5% in the past month [5] - Intuitive Surgical reported revenues of $2.25 billion for the last quarter, reflecting a year-over-year increase of +19.2% [5] - The expected earnings for Intuitive Surgical in the current quarter are $1.92 per share, indicating a +7.9% change from the previous year [6]

2025.05. 30 本文字数：1376，阅读时长大约2分钟 导读 ：家电业已经是红海，美的一边延长家电业务的生命周期，一边打造ToB业务的第二增长曲线。 作者 | 第一财经 王珍 5月30日，美的集团(000333.SZ、00300.HK，简称美的)董事长兼总裁方洪波在美的集团2024年度 股东大会上回复投资者提问时说，小米进入家电业在战略上已输了。 今年小米在空调市场掀起低价竞争，其大家电业务今年一季度收入同比实现翻倍增长。前不久，方洪 波在访谈中称"在战术上重视小米、在战略上不惧怕小米"。有投资者在美的股东大会上，追问方洪波 这句话的含义。 针对投资者关心的分红问题，方洪波表示，美的2024年分红提升，未来分红的比例在现在非常高的 基础上会进一步提升。 微信编辑 | 苏小 推荐阅读 美团公布骑手保障进展 有投资者问美的集团有没有护城河，方洪波表示，"美的没有形成自己的护城河"。他同时透露，美的 在尽量延长家电（To C）业务的生命周期，通过国内市场用户直达模式的变革、海外市场推进自主 品牌（OBM）业务；并把To B业务打造为第二增长曲线，未来希望To C和To B业务各占收入一半， 就会形成"生长接 ...

Group 1 - "Made in China 2025" aims to transform China from a "world factory" to a global high-tech manufacturing leader by 2025, with a target of 70% self-sufficiency in core components and key materials [3][4] - The initiative focuses on ten high-tech sectors, including semiconductors, robotics, new energy vehicles, aerospace, and biomedicine, supported by significant government funding and policy incentives [3][4] - From 2015 to 2022, over $1.3 trillion was invested in priority industries, with nearly 60% allocated to semiconductors and new energy vehicles, indicating a concentrated policy approach [4] Group 2 - The new energy vehicle (NEV) sector has seen remarkable success, with domestic NEVs capturing 80% of the market share in 2022, and companies like BYD ranking second globally in NEV sales [5][6] - High-speed rail has become a textbook success story, with Chinese companies now dominating the market, achieving a 90% share in high-speed rail signaling equipment [6][7] - In the new materials sector, China has significantly increased its production capacity, with a global share of 80% in petrochemical products from 2019 to 2022, and companies like Wanhua Chemical leading in the polyurethane market [7][8] Group 3 - Despite achievements, challenges remain in high-end manufacturing, particularly in semiconductors, where China's market share is only 1.9%, and reliance on imported equipment is high [8][9] - The aerospace sector faces similar issues, with the domestically produced C919 aircraft having only a 60% local content rate, heavily dependent on foreign suppliers for critical components [9][10] - The marine engineering and high-tech shipbuilding sectors also struggle, with less than 30% localization in high-tech ship equipment [10] Group 4 - The rapid advancements have led to some negative consequences, including resource wastage due to excessive government spending, with 30% of semiconductor project funds wasted on inefficient projects [11][12] - Overemphasis on industrial policy has resulted in production capacity outpacing consumer demand, leading to price wars and declining industrial profits [11][12] - In 2022, China's power battery production capacity reached 900 GWh, but actual demand was only 450 GWh, resulting in a 50% surplus [12][13] Group 5 - While China excels in low-end and mid-range markets, it still lags behind international giants in high-end sectors, with R&D investment significantly lower than that of the U.S. [13][14] - Foreign enterprises believe that Chinese competitors will take 5 to 10 years to catch up in technology, particularly in advanced fields like semiconductors and aerospace engines [14][15] - The decline in international scientific collaboration and increased trade tensions pose additional challenges for Chinese companies in sensitive technology areas [15]

炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 近日，西安大医集团股份有限公司（以下简称"大医集团"）再次递表港交所，联席保荐人为中信建投国 际、浦银国际、民银资本。此前，公司曾于2021年6月递表上交所科创板，但在半年后主动申请撤回上 市申请。 细分赛道市场空间有限 累亏7.77亿应收账款周转天数大幅延长 大医集团主营业务是创新放疗设备的研发、生产、销售、服务。按照销售额计算，大医集团在中国伽玛 放射外科医疗设备市场的所有参与者中以75.8%的市场份额排名第一，被称为"伽玛刀之王"。 亏损的主要原因在于公司在研发方面投入大量资金，招股书显示，截至2023年及2024年12月31日止年 度，大医集团研发开支分别为9790万元和1.13亿元，分别占当期毛利润的76.45%和81.71%，而研发开支 的走高主要与大医集团试图扩展业务天花板有关。 资料显示，肿瘤放疗治疗方式主要有直线加速器、伽马刀、托姆刀、质子重离子等，它们的主要区别在 于应用部位和治疗效果上。直线加速器是目前应用最为广泛的传统放疗设备，众成数科在《2023年国内 放射治疗设备市场洞察》报告中指出，2023年医用电子加速器 ...

面对巨额资金诱惑，豪洛捷方面坚定表示，企业有着清晰的长期发展战略，不愿因收购打乱节奏，更坚 信凭借自身技术与市场优势，未来价值将远超千亿。 豪洛捷作为RNA检测领域的全球领军企业，其主要产品CT(沙眼衣原体)、NG(淋球菌)、HPV检测试剂 凭借先进RNA技术，在检测准确性和灵敏度上远超同行。尤其是HPV检测产品，能精准识别多种高危 型HPV病毒，为宫颈癌早期筛查筑牢防线，在欧美市场占据极高份额。 在医疗设备领域，美股上市公司豪洛捷(HOLX)无疑是巨头级别的存在。近日，一则消息震惊了整个行 业——豪洛捷拒绝了一笔高达千亿的收购邀约。 日前，据英国《金融时报》报道，美国私募股权公司TPG与黑石集团(Blackstone)联合提出以160亿美元 (约合人民币1152亿元)收购豪洛捷。此次TPG与黑石集团提出的收购报价为每股70至72美元，以豪洛捷 5月24日收盘价54.28美元计算，若该收购达成，它将成为2025年全球医疗领域规模最大的杠杆收购之 一。 在国内，科创板上市公司仁度生物(688193)是RNA检测领域的一匹"潜力黑马"。仁度生物的创始人曾在 豪洛捷就职多年，深度参与了RNA检测技术的研发与产品迭代 ...

导读： 5月27日，新疆县域医共体设备更新项目（第三批）中标(成交)结果公告。5月26日，河南省卫生健康委员会河南省县域医共体设备更新项目（一期）项目- 全自动生化分析仪中标结果公告。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 5月2 7日，中国政府采购网发布，新疆县域医共体设备更新项目（第三批）中标(成交)结果公告，迈瑞独揽两包。中标公告显示—— 迈瑞2 2 6台生化分析仪BS- 8 3 0成功中标，成交金额为9 6 9 . 5 4万元，单价每台为4 . 2 9万元。 同时，迈瑞9 4台彩色多普勒超声诊断仪成功中标，成交金额为3 9 1 9 . 8万元，单价为4 1 . 7万元/台。 | 序号 | 标项名称 | 标的名称 品牌 | 数量 | 单价(元) 规格型号 | | | --- | --- | --- | --- | --- | --- | | | 县域医共体 | 具域医共体 | | | | | | 目(第三 | 设备更新项 设备更新项 目(第三 深圳迈瑞 | 94台 | 417000 | Recho R7Sup | | | | ...

Core Insights - The UAE is prioritizing economic diversification and has launched the "National Industrial and Advanced Technology Strategy," aiming to increase the industrial sector's contribution to GDP from 133 billion AED to 300 billion AED by 2031 [1][2] Group 1: Economic Contributions - As of 2023, the industrial sector contributes 205 billion AED to the UAE's GDP, accounting for 11% [2] - The UAE's global ranking in the United Nations Industrial Development Organization's Industrial Competitiveness Index has improved from 35th in 2019 to 27th, making it the top-ranked country in the Arab world [2] Group 2: Financing and Support Initiatives - During the "UAE Manufacturing" conference, agreements were made to provide over 40 billion AED in financing support for SMEs and innovative projects over the next five years [4] - The UAE Development Bank launched a 1 billion AED investment platform to support SMEs in strategic sectors such as manufacturing, health, food security, and advanced technology [4] Group 3: Industrial Projects and Innovations - New industrial projects announced during the event totaled 11 billion AED, showcasing over 720 companies across 12 key industrial sectors [6] - The sectors represented include food and agricultural technology, pharmaceuticals and medical devices, shipbuilding, metal processing, traditional crafts, smart manufacturing, chemicals, sustainable materials, future energy, decarbonization, electrical and electronic equipment, industrial equipment, construction materials, and aerospace and defense [6]

Investment Rating - Industry investment rating: Stronger than the market (expected to outperform the CSI 300 index by more than 5% in the next 6 months) [23] Core Viewpoints - The medical device bidding and procurement are significantly recovering, with a notable trend towards domestic substitution. Since the beginning of 2025, there has been a concentrated push for medical device updates, leading to a substantial increase in public bidding amounts, reaching a cumulative total of 11.8 billion yuan [3][10] - The procurement scale for medical devices has shown a month-on-month improvement since January 2025, with procurement amounts in January, February, March, and April being 17.4 billion yuan, 11.2 billion yuan, 14 billion yuan, and 15.3 billion yuan respectively, reflecting year-on-year growth rates of +42%, +76%, +113%, and +84% [10][3] - Major companies in the industry are benefiting from the recovery in bidding and procurement, with significant increases in procurement amounts for various devices in April 2025, including ultrasound (1.371 billion yuan, +67% YoY), CT (2.525 billion yuan, +242% YoY), and MRI (2.270 billion yuan, +191% YoY) [4][11][13] Summary by Sections Medical Device Update and Bidding Recovery - The medical device update projects are intensively advancing, with many provinces initiating collective procurement, leading to a surge in orders. The bidding process is similar to collective procurement, giving significant bargaining power to the purchasers, which benefits leading companies with comprehensive and high-end product lines [3][10] Procurement Scale and Trends - The overall scale of new medical device bidding in China is benefiting from the rapid implementation of device updates, showing a month-on-month improvement trend since the beginning of 2025. The procurement scale in April 2025 has nearly returned to the level of the same period in 2023 [10][3] Leading Companies' Performance - The bidding trends for domestic companies align closely with industry trends, with some companies showing slightly better performance. In April 2025, major domestic companies like Mindray (624 million yuan, +51% YoY), United Imaging (1.187 billion yuan, +207% YoY), and others have reported significant increases in their bidding amounts [4][17] Investment Recommendations - The report suggests focusing on leading domestic companies in the medical device sector that are enhancing their high-end and intelligent product layouts, such as Mindray Medical, United Imaging, and others. The government’s support for long-term special bonds for equipment updates is expected to positively impact industry bidding growth [5][21]

Group 1 - The core point of the news is the announcement of the selected units for the smart traditional Chinese medicine hospital pilot project, with over 80% of the selected units choosing Donghuayuan, highlighting its strong capabilities in the intelligent pharmacy sector [1] - A total of 127 units from various provinces and cities across the country have been selected for the pilot project, indicating a significant interest and investment in the modernization of traditional Chinese medicine services [1][6] Group 2 - Donghuayuan has developed a comprehensive solution for smart traditional Chinese medicine pharmacies, which integrates data and technology to create an intelligent service loop from prescription to patient medication [4] - The solution emphasizes automation and intelligence, offering customized production lines and various dosage forms, thereby improving the quality of traditional Chinese medicine and reducing patient wait times [4][5] - The smart pharmacy model represents a new service paradigm and is seen as a driving force for the innovation and modernization of traditional Chinese medicine, addressing industry challenges and enhancing service efficiency [5]